Blood Glucose, HighNCT05163587
Composite Flour and Its Antdiabetic Potential
A study testing low GI composite flour in people with Blood Glucose, High and Body Weight Changes, run by University of Veterinary and Animal Sciences, Lahore - Pakistan at 1 site in Pakistan.
Trial summary
A low glycemic multigrain flour for chapattis will be made from grains and cereals that are easily available in Pakistan. The nutritional profile and composition of test flour will be checked through proximate analysis method determined by AOAC. Read more about this study
- Who is it for?
- Ages 30 to 60 years
- Conditions the study is for
- Blood Glucose, High, Body Weight Changes, Hyperlipidemias
- What is being tested?
- low GI composite flour
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 46 participants
- Where
- 1 sitePakistan
- Study dates
- 26 Mar 2021to 30 Dec 2021
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- type 2 diabetic patients of either sex that are non insulin dependent between age 30-60 years that are on oral medication only
Who cannot join
- patients with biochemical evidence of other diseases, thyroid patients, pregnant and lactating mothers and those above the age of 60 years or those who use insulin to control their blood glucose levels
Trial locations and contacts
1 site in 1 country.
Pakistan1 site
University of Veterinary and Animal Sciences, Paksitan
Lahore, Punjab Province
About this study
Official title: Development of Low GI Composite Flour and Its Efficacy in Improving the Glycemic Profile in Type 2 Diabetes Patients _ A Randomized Clinical Trial.
A low glycemic multigrain flour for chapattis will be made from grains and cereals that are easily available in Pakistan. The nutritional profile and composition of test flour will be checked through proximate analysis method determined by AOAC. GI of test flour will be determined by comparing it with a reference food. The participants will be fed reference food i.e., 50gm glucose dissolved in 250ml water and test food serving having 50gm of available carbohydrates separately after an overnight fast. Finger prick method will be used to determine blood glucose levels at 0,15, 30, 45, 90 minutes. Trapezoidal rule will be used to determine iAUC and GI and GL will be determined by using standard formulas. Efficacy of test flour will be checked by human clinical trial. Control group will be fed chapatis made from test flour for 90 days. Anthropometry, body composition and biochemical measures including HbA1c, blood glucose (fasting and random) and lipid profile will be analyzed pre- and post-intervention and differences in their readings will be compared.
Read the detailed description
The study comprises of four different phases.
- Phase 1: To develop a low GI composite flour.
- Phase 2: To assess nutritional profile and composition of the composite flour.
- Phase 3: To determine GI of chapatis made from test flour.
- Phase 4: Test the efficacy of test flour in improving glycemic profile through clinical trial.
Subjects: A total of 30 Type 2 diabetic patients aged between 30-60 years that are on oral medication will be selected for participation. They can be of either sex with no other complications of the disease. A written consent from the participants will be taken prior to study. Those participants who have insulin dependency, thyroid issues, are smokers and pregnant and lactating mothers will be excluded from the study. Prior to study, anthropometric measurements that will include height, weight, BMI, hip to waist ratio of each participant will be done. All the participants will complete testing for their HbA1c, lipid profile, fasting and random blood glucose measurements prior to study. For this, they will be called to University of Veterinary and Animal Sciences, Lahore for their blood sample collection. All the participants will be divided into two groups: control and intervention group with 15 participants in each group. The study will be conducted for 90 days and only those participants will be recruited that will be willing to complete the study duration with all the protocols for it. These include no major change in dietary pattern during the study. No change in physical activity i.e. doing any intense exercise or following any new workout routines. No change in medications or supplements during the study period is recommended.
Experimental design: The participants in the intervention group will be provided test flour for their chapattis (2kg for 10 days). The flour will be provided after each 10 days and they will be asked to use this flour for their chapattis. They will be guided to consume at least 3-4 chapattis each day while the participants in the control group will be asked to continue the flour, they are already using for their chapatti making. However during the study period all the participants will continue to follow their regular dietary habits, physical activity patterns and will continue taking their diabetes medication as per their schedule.
Biochemical testing: Along with the anthropometry, the participants will be tested biochemically by taking their blood samples at the start and at the end of the study. Before starting the trial, each participant will be tested for HbA1c and lipid profile. HbA1c tests will be done by Ion Exchange Resin method by using Glycohemoglobin HbA1 kit of brand Human Diagnostics. Lipid profile will also be checked at the baseline and after 3 months. For this purpose, Human diagnostic Kit will be used i.e. cholesterol liquicolor kit for cholesterol assessment, HDL cholesterol kit by Human diagnostics for HDL measurement, LDL liquicolor kit and TG Liquicolor mono kit by Human Diagnostics for LDL and triglycerides assessment. Random and Fasting blood glucose levels will be checked after every 10 days by using finger prick method through Glucometer (ACCU-CHECK® Performa Nano, Mannhim, Germany). For their interpretation, Guidelines of National Cholesterol Education Program (NCEP), (2004) will be used.
Statistical analysis: Statistical Package for Social Science software ( version 22) will be used for data analysis. Independent t test will be applied to check the differences between control and intervention groups. Paired t test will be used to determine differences among groups at initial and final time points within a group and their association will be checked at significance level of <0.05. Repeated measure design will be used to compare the blood glucose levels after every 10 days.
- Being tested
- low GI composite flour
- Keywords
- hyperglycemia, hyperlipidemia, weight control, diabetes type 2
- Medical subject headings
- Body Weight Changes, Hyperlipidemias, Hyperglycemia, Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
low GI composite flourCombination product
low GI composite flour orally in chapati form (3times/day)
| Study group | Role | What they receive |
|---|---|---|
| Control | Placebo comparator | control group will be provided with the commercially available whole-wheat flour for their consumption during the study period. Receives: Combination Product: low GI composite flour |
| Intervention | Experimental | intervention group will be provided with low GI composite flour for their chapatis during study period and they will be instructed to consume at least 4 chapatis each day. Receives: Combination Product: low GI composite flour |
What is being measured
The primary outcome is the main question the study is designed to answer.
hbA1c
by using low GI composite flour, the blood glucose levels of patients with type 2 diabetes should be controlled in a better way that can be determined by their hbA1c test value in 90 days
Measured: 90 days
blood glucose levels
by incorporating low GI food in daily meals will help lower the readings of daily blood glucose levels in patients with type 2 diabetes
Measured: weekly
lipid profile
lipid profile of patients with type 2 diabetes will be improved
Measured: 90 days
Secondary outcomes (2)
body weight
by keeping blood glucose levels in control and incorporating high fiber multigrain flour, it is expected that body weight of diabetic type 2 patients will be controlled in better way.
Measured: 90 days
body composition
body composition of participants will be measured through BIA
Measured: 90days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2021
- Study start26 Mar 2021
- Primary completion5 Dec 2021
- Study completion30 Dec 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Blood Glucose, HighStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- two arm parallel assignment
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Veterinary and Animal Sciences, Lahore - Pakistan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sanaullah Iqbal, University of Veterinary and Animal Sciences, Lahore - Pakistan
- Investigators
- Azka Adeeb Alvi, Mphil, Principal investigator, University of Veterinary and Animal Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05163587
- Sponsor's protocol ID
- Composite flour
- Status last verified
- Jan 2024
- First submitted
- 24 Jun 2021
- Last updated
- 23 Jan 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development of Low GI Composite Flour and Its Efficacy in Improving the Glycemic Profile in Type 2 Diabetes Patients _ A Randomized Clinical Trial.
- ClinicalTrials.gov ID
- NCT05163587
- Acronym / sponsor ID
- Composite flour
- Keywords
- hyperglycemia, hyperlipidemia, weight control, diabetes type 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- University of Veterinary and Animal Sciences, Lahore - PakistanUniversity, hospital or other
- Study start
- 26 Mar 2021 (actual)
- Primary completion
- 5 Dec 2021 (actual)
- Study completion
- 30 Dec 2021 (actual)
- First posted
- 20 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A low glycemic multigrain flour for chapattis will be made from grains and cereals that are easily available in Pakistan. The nutritional profile and composition of test flour will be checked through proximate analysis method determined by AOAC. GI of test flour will be determined by comparing it with a reference food. The participants will be fed reference food i.e., 50gm glucose dissolved in 250ml water and test food serving having 50gm of available carbohydrates separately after an overnight fast. Finger prick method will be used to determine blood glucose levels at 0,15, 30, 45, 90 minutes. Trapezoidal rule will be used to determine iAUC and GI and GL will be determined by using standard formulas. Efficacy of test flour will be checked by human clinical trial. Control group will be fed chapatis made from test flour for 90 days. Anthropometry, body composition and biochemical measures including HbA1c, blood glucose (fasting and random) and lipid profile will be analyzed pre- and post-intervention and differences in their readings will be compared.
Detailed description
The study comprises of four different phases.
- Phase 1: To develop a low GI composite flour.
- Phase 2: To assess nutritional profile and composition of the composite flour.
- Phase 3: To determine GI of chapatis made from test flour.
- Phase 4: Test the efficacy of test flour in improving glycemic profile through clinical trial.
Subjects: A total of 30 Type 2 diabetic patients aged between 30-60 years that are on oral medication will be selected for participation. They can be of either sex with no other complications of the disease. A written consent from the participants will be taken prior to study. Those participants who have insulin dependency, thyroid issues, are smokers and pregnant and lactating mothers will be excluded from the study. Prior to study, anthropometric measurements that will include height, weight, BMI, hip to waist ratio of each participant will be done. All the participants will complete testing for their HbA1c, lipid profile, fasting and random blood glucose measurements prior to study. For this, they will be called to University of Veterinary and Animal Sciences, Lahore for their blood sample collection. All the participants will be divided into two groups: control and intervention group with 15 participants in each group. The study will be conducted for 90 days and only those participants will be recruited that will be willing to complete the study duration with all the protocols for it. These include no major change in dietary pattern during the study. No change in physical activity i.e. doing any intense exercise or following any new workout routines. No change in medications or supplements during the study period is recommended.
Experimental design: The participants in the intervention group will be provided test flour for their chapattis (2kg for 10 days). The flour will be provided after each 10 days and they will be asked to use this flour for their chapattis. They will be guided to consume at least 3-4 chapattis each day while the participants in the control group will be asked to continue the flour, they are already using for their chapatti making. However during the study period all the participants will continue to follow their regular dietary habits, physical activity patterns and will continue taking their diabetes medication as per their schedule.
Biochemical testing: Along with the anthropometry, the participants will be tested biochemically by taking their blood samples at the start and at the end of the study. Before starting the trial, each participant will be tested for HbA1c and lipid profile. HbA1c tests will be done by Ion Exchange Resin method by using Glycohemoglobin HbA1 kit of brand Human Diagnostics. Lipid profile will also be checked at the baseline and after 3 months. For this purpose, Human diagnostic Kit will be used i.e. cholesterol liquicolor kit for cholesterol assessment, HDL cholesterol kit by Human diagnostics for HDL measurement, LDL liquicolor kit and TG Liquicolor mono kit by Human Diagnostics for LDL and triglycerides assessment. Random and Fasting blood glucose levels will be checked after every 10 days by using finger prick method through Glucometer (ACCU-CHECK® Performa Nano, Mannhim, Germany). For their interpretation, Guidelines of National Cholesterol Education Program (NCEP), (2004) will be used.
Statistical analysis: Statistical Package for Social Science software ( version 22) will be used for data analysis. Independent t test will be applied to check the differences between control and intervention groups. Paired t test will be used to determine differences among groups at initial and final time points within a group and their association will be checked at significance level of <0.05. Repeated measure design will be used to compare the blood glucose levels after every 10 days.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
- Model description
- two arm parallel assignment
| Arm | Type | Receives |
|---|---|---|
| Control | Placebo comparator | Combination Product: low GI composite flourcontrol group will be provided with the commercially available whole-wheat flour for their consumption during the study period. |
| Intervention | Experimental | Combination Product: low GI composite flourintervention group will be provided with low GI composite flour for their chapatis during study period and they will be instructed to consume at least 4 chapatis each day. |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- type 2 diabetic patients of either sex that are non insulin dependent between age 30-60 years that are on oral medication only
Key exclusion criteria (1 listed)
- patients with biochemical evidence of other diseases, thyroid patients, pregnant and lactating mothers and those above the age of 60 years or those who use insulin to control their blood glucose levels
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| low GI composite flourlow GI composite flour orally in chapati form (3times/day) | Combination product | Control, Intervention |
Primary outcome
hbA1c
Time frame: 90 days
by using low GI composite flour, the blood glucose levels of patients with type 2 diabetes should be controlled in a better way that can be determined by their hbA1c test value in 90 days
blood glucose levels
Time frame: weekly
by incorporating low GI food in daily meals will help lower the readings of daily blood glucose levels in patients with type 2 diabetes
lipid profile
Time frame: 90 days
lipid profile of patients with type 2 diabetes will be improved
2 secondary outcomes
body weight
Time frame: 90 days
body composition
Time frame: 90days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Jan 2024.
Related trials for Blood Glucose, High
Enrolling by invitation
MTM2MTG Pilot Ancillary Study
Diet, Healthy, HbA1c
RecruitingPhase 1
Understanding the Health Effect of a Bioactive Peptide From Egg: A Pilot Study
High Blood Sugar, High Blood Pressure
Recruiting
HUGO-SLEEVE: Evaluating the Feasibility of Robotic Sleeve Gastrectomy With a New Platform
Obesity (BMI > 35), Obesity (BMI > 35) and Diabetes Mellitus
Active, not recruitingObservational study
Maternal and Cord Blood MST1 Levels in Gestational Diabetes Mellitus
Gestatiaonl Diabetes Mellitus
Active, not recruiting
Remotely Delivered Resistance Training for Cardiometabolic Health Among Black Women
Overweight or Obesity, Prediabetes or Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Azka Adeeb Alvi, Mphil principal investigator
University of Veterinary and Animal Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing low GI composite flour in people with Blood Glucose, High and Body Weight Changes, run by University of Veterinary and Animal Sciences, Lahore - Pakistan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
hbA1c (time frame: 90 days). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Jan 2024.